October 17, 2019 07:49 AM EDT

Despite worries triggered by imbalance of deaths, Shionogi's antibiotic clears FDA panel vote

Amber Tong

Concerns over disproportionate mortality had not stopped a panel of experts to recommend that the FDA approve Shionogi’s antibiotic cefiderocol for complicated urinary tract infections …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Despite worries triggered by imbalance of deaths, Shionogi's antibiotic clears FDA panel vote

Amber Tong

Sign up to read this article for free.

Updated: Amgen obesity shot shows 20% weight loss, but dosing questions hang over readout

The Biden administration wants Medicare and Medicaid to cover GLP-1s. Will the Trump White House allow it?

Sarepta licenses Arrowhead's RNA-based rare disease pipeline, promising big biobucks

Updated: Roche buys out CAR-T partner Poseida for $1B upfront

Axsome moves toward NDA filing for narcolepsy drug following positive Phase 3 data

Roche’s TIGIT drug misses last shot at survival endpoint win in Phase 3 lung cancer trial

De­spite wor­ries trig­gered by im­bal­ance of deaths, Sh­ionogi's an­tibi­ot­ic clears FDA pan­el vote

Amber Tong

Sign up to read this article for free.

more like this

Up­dat­ed: Am­gen obe­si­ty shot shows 20% weight loss, but dos­ing ques­tions hang over read­out

The Biden ad­min­is­tra­tion wants Medicare and Med­ic­aid to cov­er GLP-1s. Will the Trump White House al­low it?

Sarep­ta li­cens­es Ar­row­head­'s RNA-based rare dis­ease pipeline, promis­ing big biobucks

Up­dat­ed: Roche buys out CAR-T part­ner Po­sei­da for $1B up­front

Ax­some moves to­ward NDA fil­ing for nar­colep­sy drug fol­low­ing pos­i­tive Phase 3 da­ta

Roche’s TIG­IT drug miss­es last shot at sur­vival end­point win in Phase 3 lung can­cer tri­al

Despite worries triggered by imbalance of deaths, Shionogi's antibiotic clears FDA panel vote

Updated: Amgen obesity shot shows 20% weight loss, but dosing questions hang over readout

The Biden administration wants Medicare and Medicaid to cover GLP-1s. Will the Trump White House allow it?

Sarepta licenses Arrowhead's RNA-based rare disease pipeline, promising big biobucks

Updated: Roche buys out CAR-T partner Poseida for $1B upfront

Axsome moves toward NDA filing for narcolepsy drug following positive Phase 3 data

Roche’s TIGIT drug misses last shot at survival endpoint win in Phase 3 lung cancer trial